Sharekhan

Supriya Lifescience Ltd

Wed 11/06/2025,15:55:25 NSE: SUPRIYA

₹ 680.50 0.60 (0.09%)
BUY NOW Buy Supriya Lifescience Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Supriya Lifescience Ltd

Wed 11/06/2025,16:1:0

Supriya Lifescience Ltd

Wed 11/06/2025,15:55:25 | NSE : SUPRIYA

₹ 680.500.60 (0.09%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 679.90

Previous Close

₹ 679.90

Volume

288565

Mkt Cap ( Rs. Cr)

₹5476.85

High

₹ 695.00

Low

₹ 676.25

52 Week High

₹ 842.00

52 Week Low

₹ 356.00

Book Value Per Share

₹ 112.56

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Supriya Lifescience Ltd

Your Vote -

Buy

65.91%

Hold

5.68%

Sell

28.41%

65.91%

88 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

680.50

388

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

388

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Supriya Lifescience Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    31 May 2025, 5:15PM Please find attached Earnings Call Transcript for the Earnings call held on May 28, 2025 with respect to Audited Financial Results of the Company for

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    31 May 2025, 5:15PM Supriya Lifescience Limited has informed the Exchange about Transcript

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    28 May 2025, 2:48PM Supriya Lifescience Limited has informed the Exchange about Link of Recording

  • Supriya Lifescience - Copy of Newspaper Publication

    28 May 2025, 2:42PM Press Release- Audited Financial Results for the quarter and year ended March 31, 2025

  • Supriya Lifescience - Press Release

    28 May 2025, 2:37PM Please find attached Press Release

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    28 May 2025, 2:49PM Please find attached Audio Recording of Earnings Call.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    28 May 2025, 2:38PM Please find attached herewith Press Release

  • Supriya Lifescience - Investor Presentation

    27 May 2025, 7:42PM Supriya Lifescience Limited has informed the Exchange about Investor Presentation

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Investor Presentation

    27 May 2025, 7:42PM Please find enclosed herewith a copy of Investor Presentation.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Dividend Updates

    27 May 2025, 6:45PM Recommended Dividend of Final Dividend of Re. 1.00 (Rupee 1.00/-) per equity share i.e. 50% on the face value of Rs. 2/- each, subject to approval of

  • Supriya Lifescience - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    27 May 2025, 6:27PM SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer

  • Supriya Lifescience - Outcome of Board Meeting-XBRL

    27 May 2025, 6:24PM SUPRIYA LIFESCIENCE LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 27-May-2025 for Dividend

  • Supriya Lifescience - Change in Auditors

    27 May 2025, 6:21PM Supriya Lifescience Limited has informed the Exchange regarding Change in Auditors of the company.

  • Supriya Lifescience - Appointment Of Secretarial Auditor For Term Of Five (5) Consecutive Years

    27 May 2025, 6:16PM Appointment of Auditors for Term of five (5) consecutive years

  • Supriya Lifescience - Dividend

    27 May 2025, 6:13PM Supriya Lifescience Limited has informed the Exchange that Board of Directors at its meeting held on May 27, 2025, recommended Final Dividend of Re. 1

  • Supriya Lifescience - Corporate Action-Board to consider Dividend

    27 May 2025, 6:11PM Board recommended Final Dividend at its meeting held on May 27, 2025

  • Supriya Lifescience - Audited Financial Result For Quarter And Year Ended On March 31, 2025

    27 May 2025, 6:09PM Audited Financial Results for the year ended March 31, 2025

  • Supriya Lifescience - Outcome of Board Meeting

    27 May 2025, 6:00PM Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

  • Supriya Lifescience - Dividend

    27 May 2025, 5:53PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience - Board Meeting Outcome for Outcome Of Board Meeting Held On May 27, 2025

    27 May 2025, 5:53PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directo

  • Supriya Lifescience Q4 net profit up 36.42% at Rs 50.38 cr

    27 May 2025, 5:52PM The company reported standalone net profit of Rs 50.38 crore for the quarter ended March 31, 2025 as compared to Rs 36.93 crore in the same period las

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    21 May 2025, 5:18PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 May 2025, 5:19PM Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call wil

  • Supriya Lifescience - Board Meeting Intimation

    20 May 2025, 5:18PM SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 27-May-2025 to consider and approve the Yearly Audited Financi

  • Supriya Lifescience - Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended Ma

    20 May 2025, 5:16PM Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2025 ,inter alia, to consider

  • Supriya Lifescience - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    28 Apr 2025, 12:31PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Supriya Lifescience - Shareholders meeting

    24 Apr 2025, 5:10PM Supriya Lifescience Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange reg

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    24 Apr 2025, 5:13PM The Scrutinizers' report & Voting Results for the Postal ballot conducted by the Company is attached herewith.

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    24 Apr 2025, 5:11PM The Voting Results and Scrutinizers' Report for the Postal Ballot conducted by the Company is attached herewith.

  • Supriya Lifescience has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    17 Apr 2025, 5:20PM As of March 2025, 68.30% is owned by Indian Promoters and 31.70% by Public. <p align=justify> Institutional holds 11.45% (Insurance Companies 1.70%) a

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    15 Apr 2025, 5:27PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 Apr 2025, 5:28PM Enclosed herewith details of Analyst/Institutional Investor Meeting.

  • Supriya Lifescience - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 4:58PM Company has informed the exchange about certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2025

  • Supriya Lifescience - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 4:57PM Company has informed exchanges about certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2025.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Apr 2025, 5:16PM Enclosed herewith details of Analyst/Institutional Investor Meetings.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Apr 2025, 5:17PM Enclosed herewith details of Analyst/Institutional Investor Meetings.

  • Supriya Lifescience - Trading Window-XBRL

    26 Mar 2025, 5:30PM Supriya Lifescience Limited has informed the Exchange about Closure of Trading Window

  • Supriya Lifescience - Trading Window

    26 Mar 2025, 5:26PM Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Supriya Lifescience - Copy of Newspaper Publication

    25 Mar 2025, 4:38PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication for Postal Ballot

  • Supriya Lifescience - Notice Of Shareholders Meetings-XBRL

    24 Mar 2025, 4:29PM Supriya Lifescience Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot

  • Supriya Lifescience - Shareholders meeting

    24 Mar 2025, 4:27PM Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    24 Mar 2025, 4:24PM Please find attached Postal Ballot Notice of Supriya Lifesciences Limited

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Mar 2025, 5:49PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, the details of the Analyst/Investor Meetings to be attended by the Company are as enclosed h

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Mar 2025, 5:46PM Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the details of the Analyst/ Investor Meetings to be attended by the Company are enclosed h

  • Supriya Life

    29 Sep 2022 , 11:11AM The company gets European drug body's approval for antihistamine drug. Diphenhydramine Hydrochloride is an antihistamine that reduces the effects of natural chemical histamine in the body. It is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms – Positive read through for the stock.

  • Supriya Life gets European drug body's approval for antihistamine drug

    29 Sep 2022 , 9:41AM EDQM grants Certification of Suitability for Diphenhydramine Hydrochloride, API in AntiHistamine therapy
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Supriya Lifescience Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 996.76 815.368 716.083 636.983 335.993
Liabilities 996.76 815.368 716.083 636.983 335.993
Equity 16.097 16.097 16.097 16.097 14.637
Gross Profit 260.796 172.976 128.897 213.984 167.295
Net Profit 187.958 119.114 89.857 151.81 123.593
Cash From Operating Activities 164.676 113.307 66.187 48.801 78.905
NPM(%) 26.98 20.88 19.49 28.64 32.07
Revenue 696.485 570.37 460.938 530.049 385.366
Expenses 435.689 397.394 332.041 316.065 218.071
ROE(%) 20.74 13.14 9.91 16.75 13.64

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
1 50 0 729.7
20 Sep 2024 0.8 40 0 363.1
15 Sep 2023 0.6 30 0 256.65
01 Sep 2022 0.6 30 0 378.15

Peers

Other companies within the same industry or sector that are comparable to Supriya Lifescience Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 855.40 0.52 28.38 387.72 301.39 0.58
Lotus Eye Hospital and Institute Ltd 72.06 -1.95 205.89 1412.80 3.55 0.00
Vaishali Pharma Ltd 12.58 -2.25 209.67 728.21 3.13 0.00
Astec Lifesciences Ltd 808.70 -0.33 0.00 1332.15 -687.10 0.00

Company Info

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022 -Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'. 2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". --Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022 -Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'. 2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". --Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.

Read More

Parent Organisation

Supriya Lifescience Ltd.

Founded

26/03/2008

Managing Director

NSE Symbol

SUPRIYAEQ

FAQ

The current price of Supriya Lifescience Ltd is ₹ 680.50.

The 52-week high for Supriya Lifescience Ltd is ₹ 695.00 and the 52-week low is ₹ 676.25.

The market capitalization of Supriya Lifescience Ltd is currently ₹ 5476.85. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Supriya Lifescience Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Supriya Lifescience Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Supriya Lifescience Ltd shares.

The CEO of Supriya Lifescience Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT